Media Relations News Releases Year: - Any -201820172016 Items per page 102550 Nov 29, 2017 Summary ToggleNovartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab (AMG334) in migraine prevention Nov 10, 2017 Summary ToggleNovartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants Nov 10, 2017 Summary ToggleNovartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness Nov 7, 2017 Summary ToggleNovartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage Nov 6, 2017 Summary ToggleNovartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years Oct 30, 2017 Summary ToggleNovartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA Oct 28, 2017 Summary ToggleNovartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a Sep 16, 2017 Summary ToggleNovartis’ Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption Sep 13, 2017 Summary ToggleNovartis’ Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data Sep 7, 2017 Summary ToggleNovartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies Pagination First page First Previous page Previous … Page 3 Current page 4 Page 5 Page 6 … Next page Next Last page Last
